These are the best biotech companies based in Stevenage, an English city that has become a center of life sciences that competes with such as London, Oxford and Cambridge.
The life sciences scene of the UK is mostly centered around the Golden Triangle of London, Oxford and Cambridge. Located right in the middle of this triangle, the city of Stevenage has established itself as a biotechnology center over the past decade.
In 2010, Stevenage BioScience Catalyst (SBC) was founded as a result of a collaboration between the UK government and the major pharmaceutical company GSK. “There are large organizations on campus, including GSK, Cell and Gene therapy The Catapult, LifeArc and Cytiva production center along with a growing cluster of more than 40 startups, ” said Sally Ann Forsythe, CEO of SBC.
Within easy reach of the Golden Triangle academic centers SBC has quickly grown into the largest cluster of cell and gene therapy companies in Europe. Total private equity investment in biotechnology raised at Stevenage over the past four years is similar to investment in Cambridge, Oxford and London. For comparison, the average deal size in Stevenage was more than five times more than other clusters.
“Stevenage is less well known than some of the UK’s major university cities, but is a gem of a place. It offers easy access to London by train, and is close to the research center of the major pharmaceutical company GSK, so provides a pool of like-minded scientists for networking and recruitment. “ said Roberto Solari, CEO and co-founder of Myricx Pharma, a biotechnology company based in Stevenage.
With further investment expected to pour into Stevenage biotechnology center According to GSK, over the next decade the success of companies based in this cluster will only grow over time.
Achilles Therapeutics, based in London and Stevenage, is developing a personalized T-cell therapy against cancer using a type of immune cell known as tumor infiltrating lymphocytes (TIL). The company’s approach is to isolate TIL from the patient and select those that target cancer neoantigens – mutated proteins present only in tumor cells.
Achilles Therapeutics is currently conducting phase I / II clinical trials in patients with lung cancer and melanoma. In March 2021, the company completed an IPO on the Nasdaq followed by a wave of investment in biotechnology companies targeting neoantigens for cancer treatment.
Autifony Therapeutics is a branch of the major pharmaceutical company GSK, which has its UK research center in Stevenage. The company is developing drugs for genetic disorders of the central nervous system as well as hearing impairments. Autifony treatment targets ion channel proteins that are required for neuronal activity.
Among other things, the firm is testing its Phase I candidate as a treatment for schizophrenia and fragile X syndrome genetic disease. Last year, Autifony Therapeutics signed a contract with Boehringer Ingelheim to develop drugs to treat Parkinson’s disease and other related diseases.
Developed by Autolus Therapeutics, a branch of University College London CAR-T cell therapy of cancer. The approach consists of engineered T cells extracted from the patient to improve their ability to find and destroy cancer cells.
The company expects to obtain data from key clinical trials on patients with acute myeloid leukemia in 2022. Its pipeline includes cells that have been designed to identify two cancer targets simultaneously, as well as treatments for solid tumors that are currently a major challenge for CAR-T Therapy to address.
Freeline Therapeutics develops methods of gene therapy for chronic genetic diseases. The company’s technology, which originated at University College London, uses adeno-associated viruses to provide gene therapy that can fight more complex genetic diseases than existing treatments.
In late 2021, Freeline Therapeutics received positive preliminary data from two ongoing phase I / II clinical trials on hemophilia B and Fabry disease. In early 2022, the company will begin a third clinical study of Phase I / II Gaucher disease.
Based in Copenhagen and Stevenage, Galecto is developing treatments for diseases related to fibrosis, inflammation and cancer. The company focuses on galectins, a group of proteins involved in the pathological generation of scar tissue known as fibrosis, as well as inflammation and cancer. Together, these proteins are associated with a wide range of conditions in different organs.
Galecto is currently conducting four phase II trials for cancer and fibroids. In 2022, the company expects to get results from its programs on myelofibrosis and lung cancer.
Based in London and Stevenage, ImmTune Therapies aims to simplify cell therapy production to reduce the massive cost of producing these treatments and make them more accessible to patients. The goal is CAR-T cancer therapies, which are currently produced individually by developing the patient’s own immune cells. The company is developing an alternative method of creating cells directly inside the patient’s body that will significantly reduce the cost and time required to manufacture and perform these treatments.
Myricx Pharma is a drug-based startup that targets an enzyme known as N-myristoyltransferase (NMT), which makes changes in the proteins in our cells that are necessary for their function. Early research has shown that NMT may be a very effective target against cancer caused by mutations in MYC genes that have so far been considered unfit for treatment. The company will also focus on viral infections, including the rhinovirus, which is responsible for most colds.
The company was launched in 2020 with an investment of 5.4 million euros (4.5 million pounds) from venture investors in the life sciences. Its technology is based on research from Imperial College London and the Francis Creek Institute.
Isolated from GSK, NeRRe Therapeutics focuses on developing orvepitant, a candidate drug for the treatment of chronic cough. The drug has shown its effectiveness in patients with chronic refractory cough with a high frequency of cough, and now the company plans to test it for the treatment of cough in patients with idiopathic pulmonary fibrosis.
In July 2021, the company received an investment of 20 million euros of B2 series, which will fund the preparation for phase IIb trials in patients with idiopathic pulmonary fibrosis.
Based in Philadelphia and Stevenage, Ossianix is developing treatments inspired by shark antibodies. Their small size allows them to cross the blood-brain barrier and target the brain, which is a problem for most drugs.
The company runs preclinical programs on neurodegenerative diseases, including amyotrophic lateral sclerosis, autoimmune diseases, pain, and botulism. Ossianix has also shown that its antibodies can be effective against Covidence of covid-19 infection.
ReViral is developing antiviral treatments targeting the respiratory syncytial virus (RSV), which kills hundreds of thousands of people each year. The virus seriously affects children, the elderly and people with weakened immune systems. However, there are no FDA-approved treatments for RSV in adults, only in children.
The company is conducting two phase II trials with its flagship candidate, one for infants and the other for adults.
https://www.labiotech.eu/best-biotech/biotech-companies-stevenage-uk/ Top 10 Biotech Companies in Stevenage, Hidden Stone of Life Sciences UK